Opens in a new tab or window Use of SGLT2 inhibitors before emergency surgery was not associated with an increased risk for postoperative diabetic ketoacidosis ... study to date examining the ...

Diabetic ketoacidosis (DKA) is a build-up of substances called ketones in the blood that can happen if a patient's blood glucose levels are too high for too long and is caused by a lack of insulin ...

We sought to describe their association with euglycemic diabetic ketoacidosis (euDKA) in hopes that it will enhance recognition of this potentially life-threatening complication. Research Design ...

A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide. In affected people, insulin is unable to ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

NPR's Up First is the news you need to start your day. The three biggest stories of the day, with reporting and analysis from NPR News — in 10 minutes. Available weekdays at 6:30 a.m. ET ...

Once a week Reuters Weekend Briefing Has it been a busy week? Sign up for our recap, sent on Saturdays, to catch up on the stories you may have missed. Once a week Reuters Politics U.S. Latest ...

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

Do CD rates go up with the prime rate? The prime rate is a benchmark widely used by banks when setting interest rates. Returns on savings accounts, interest-bearing checking accounts and CDs ...

such as diabetic ketoacidosis. Teplizumab is thought to work by preventing the activation of T-cells that attack those cells. In a clinical trial, Tzield given once daily as an intravenous ...